OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant
Nariko Ikemura, Shunta Taminishi, Tohru Inaba, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Nariko Ikemura, Shunta Taminishi, Tohru Inaba, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Showing 13 citing articles:
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 68
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 68
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV ‐2
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 11
Open Access | Times Cited: 45
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 11
Open Access | Times Cited: 45
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
Brandon Havranek, Graeme Walker Lindsey, Yusuke Higuchi, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 11
Brandon Havranek, Graeme Walker Lindsey, Yusuke Higuchi, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 11
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 2
In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants
Jenny Andrea Arévalo-Romero, Gina López-Cantillo, Sara Moreno-Jiménez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10802-10802
Open Access | Times Cited: 2
Jenny Andrea Arévalo-Romero, Gina López-Cantillo, Sara Moreno-Jiménez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10802-10802
Open Access | Times Cited: 2
Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps
Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, et al.
Structure (2023) Vol. 31, Iss. 3, pp. 253-264.e6
Open Access | Times Cited: 4
Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, et al.
Structure (2023) Vol. 31, Iss. 3, pp. 253-264.e6
Open Access | Times Cited: 4
A decoy mutant ACE2 designed to reduce COVID-19
Mazharul Maishan, Diana L. Lim, Guy A. Zimmerman, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 9, pp. 703-705
Open Access | Times Cited: 1
Mazharul Maishan, Diana L. Lim, Guy A. Zimmerman, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 9, pp. 703-705
Open Access | Times Cited: 1
Recombinant Human ACE2-Fc : A promising therapy for SARS-CoV2 infection
P.K Smitha, R.K. Shandil, Pushkarni Suresh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
P.K Smitha, R.K. Shandil, Pushkarni Suresh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps
Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
